FDA Proactive Stance Toward Drug Development Urged By Consumer Reps
This article was originally published in The Tan Sheet
Executive Summary
Despite recent improvements, heightened agency communication and transparency are needed in the development of drugs and other health-related matters, consumer advocates told FDA staffers at the agency's Roundtable on Consumer Protection Priorities in Washington, D.C., Dec. 13.
You may also be interested in...
NIH Microbicide R&D Workshop To Develop Plan For HIV Strategy
The NIH Office of AIDS Research will convene a planning workshop to develop a strategic plan for microbicide research and development Nov. 8. The outline will be incorporated into the agency's FY 2002 strategic plan for HIV-related research.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands